https://orcid.org/0000-0002-7874-5585
Summary
RMC-7977 is a new pan-RAS inhibitor, exhibiting activity against various RAS mutations and demonstrated groundbreaking efficacy in pancreatic cancer patients. It functions by forming a tri-complex with RAS and cyclophilin A (CYPA), inhibiting the active state of both mutant and wild-type RAS. Neurofibromatosis type 1 (NF1) is a tumor pre-disposition syndrome caused by alterations in neurofibromin 1 (NF1), a suppressor of RAS, leading to hyperactive RAS pathway. Here, we investigated the preclinical effect of RMC-7977 on NF1-related tumors and demonstrated significant therapeutic efficacy in various NF1 xenograft mouse models, including malignant peripheral nerve sheath tumor (MPNST) and glioma
Accepted manuscriptsAccepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.
PDF
This content is only available as a PDF.
© The Author(s) 2025. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].
